From idea, to lab, to clinic, to approval—it's a long and expensive process to bring a drug to market. It also rarely ...

A new AI model called popEVE can predict how likely each variant in a patient’s genome is to cause disease. The team is ...

In this interview, Kalpana Barnes highlights how new approach methodologies are addressing the gaps in drug discovery studies ...

Organoid-on-chip technology merges patient-derived organoids with microfluidic engineering to recreate human physiology and ...

A major new initiative involving Leicester experts aims to redefine human-based research models for greater understanding of ...

The passage of the FDA Modernization Act 2.0 in 2022 has provided additional impetus to develop new approach methods for predicting the effects of drug candidates in humans from models such as ...

The models can be used to plan surgeries and in the future could be used to help trial new drugs. A healthy heart beats at a steady rate, between 60 and 100 times a minute. That’s not the case for all ...

Drug discovery programs require a robust panel of models and assays to identify and validate drug targets, support compound optimisation, and run mechanistic studies. Fully human in vitro model ...

Artificial intelligence has been working its way into the drug development process for years now, but with little to show so far in revamping the notoriously burdensome process. While drugs are being ...

Genetically-humanized FcRn mice provide translational pharmacokinetics (PK) and pharmacodynamics (PD) data for antibody-based therapeutics. The image illustrates a therapeutic antibody (blue) adhering ...

The Food and Drug Administration and National Institutes of Health held a joint workshop July 7 on reducing animal testing in research, strikingly announcing that “NIH will no longer seek proposals ...